Congress caps drug costs for patients, expands Medicare negotiation power

What it does

This bill expands Medicare's drug price negotiation program to cover more drugs (up to 50 per year instead of a lower number), applies it to commercial insurance plans on a voluntary basis, extends inflation rebates to drugs sold outside Medicare, and caps out-of-pocket costs for prescription drugs in private insurance at $2,000 per year starting in 2027, with insulin capped at $35 per 30-day supply. Ordinary people with private insurance and Medicare beneficiaries benefit through lower drug costs and predictable out-of-pocket limits; pharmaceutical manufacturers face lower negotiated prices.

Why we flagged it

The bill's operative mechanism is a three-part price restraint: expanding Medicare negotiation authority, extending inflation rebates to commercial markets, and capping patient out-of-pocket costs. These are direct price controls and consumer protections, not subsidies or deregulation.

What the text implies

• Voluntary participation by commercial insurers may create a two-tier system: plans that opt in (lower drug costs) vs. plans that opt out (higher costs). Public disclosure of opt-outs may pressure insurers to participate, but the mechanism is permissive, not mandatory.
• The bill repeals Section 71203 of Public Law 119–21, reversing a prior restriction on the negotiation program. This is a direct legislative reversal of a recent change, signaling ongoing political volatility in drug pricing policy.
• Insulin pricing is capped at $35 per 30-day supply or 25% of negotiated price (whichever is lower), but only for 'selected insulin products' chosen by the plan. Plans retain discretion over which insulins qualify, potentially limiting choice.
• Out-of-pocket limits sunset on January 1, 2027, meaning they expire unless Congress reauthorizes. This creates a cliff risk for consumers and uncertainty for insurers planning coverage.
• The bill applies negotiated prices to both Medicare and commercial markets, but commercial insurers can opt out. This creates a regulatory asymmetry: Medicare beneficiaries get mandatory price controls; commercial enrollees depend on insurer choice.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens gain concrete protections: capped out-of-pocket drug costs ($2,000/year, $35 insulin), expanded price negotiation reducing drug prices, and inflation rebates. Pharmaceutical companies face revenue pressure, but that is a cost to industry, not citizens. The bill's primary mechanism restricts what drug makers can charge, not what citizens can access or claim.

Who stands to gain

• Medicare beneficiaries (lower drug costs)
• Uninsured and underinsured individuals (if commercial plans pass savings through)
• Patients with chronic conditions requiring expensive drugs (insulin, biologics)

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS), Pharmaceutical manufacturers (JNJ, BMY, others), Health insurers (AIG, PRU, FBK), Pharmacy Benefit Managers (PBMs), Medicare Part D plans, Group health plans, Individual health insurance issuers

Where it stands

58 cosponsors: 58 Democrats.

• Nov 20, 2025 — Introduced · Congress.gov: “Introduced in House”
• Nov 20, 2025 — Referred to House Committee on Education and Workforce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 5 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $4,411,000 in lobbying spend. A filing names 41 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Frank Pallone, the sponsor, reported $1,601,749 in PAC receipts in the 2026 cycle. $1,000 of that came from 1 PAC tied to these lobbying clients.

• Amgen Inc — $2,440,000 on 1 filing
• American Federation of State County and Municipal Employees — $690,000 on 1 filing
• Astrazeneca Pharmaceuticals Lp — $670,000 on 1 filing
• Communications Workers of America — $431,000 on 1 filing
• Lundbeck LLC — $180,000 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.